The BRAVO Trial was supported through grants from the National Institutes of Health National Institute on Drug Abuse (R01DA037441, UG1DA015815). Grant UL1TR002369 provided support of REDCap, the web application this study used for data collection. NIH Build EXITO: RL5GM118963, UL1GM118963, TL4GM118965
Date of Award
Bachelor of Science (B.S.) in Science and University Honors
Buprenorphine -- Therapeutic use, Naloxone -- Therapeutic use, Methadone maintenance, Quality of life, Drug addicts -- Vietnam, HIV-positive persons -- Vietnam, Opioid abuse
Health-related Quality of Life (QoL) is generally poorer in individuals with opioid use disorder (OUD) in comparison with those suffering from other chronic diseases. Little is known about the difference each buprenorphine/naloxone (BUP/NX) or methadone maintenance therapy (MMT) may make in the QoL for the HIV-infected people with OUD who are new to HIV care. The objective of this study is to evaluate the difference in the impact that BUP/NX and MMT treatment delivery models make on the QoL of the HIV-infected participants with OUD in Vietnam.
This study was a subset of the BRAVO study, buprenorphine to improve HIV care engagement and outcomes: a randomized trial. This study analyzed the QoL data from 254 participants (121 participants belonging to the BUP/NX group), excluding 30 due to lack of follow-up assessments, based on EUROQOL’s EQ-5D instrument standards.
Examination of the 5-level Likert scale of the five dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression over 12 months suggests both treatment delivery models tend to improve QoL for the patients of such cohort, but not in all dimensions. Self-care and activity level were two of the dimensions which did not seem affected by either of the treatment delivery models. And the BUP/NX randomized group demonstrated more favorable improvements in the mobility and pain dimensions while anxiety levels were improved almost equally in both groups.
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/ This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
Mirzazadeh Javaheri, Ali, "Differential Effects of Buprenorphine/Naloxone Vs. Methadone on Quality of Life Over Time: A Subset of The BRAVO Study (Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial)" (2020). University Honors Theses. Paper 953.
Available for download on Wednesday, February 02, 2022